Trifluridine-Tipiracil + Bevacizumab (SUNLIGHT) — 3L+ mCRC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TRIFLURIDINE-TIPIRACIL DRUG-BEVACIZUMAB |
|---|
| ID | REG-TRIFLURIDINE-TIPIRACIL-BEV |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Notes
SUNLIGHT trial (Prager 2023): 3L+ mCRC after standard chemo — TAS-102 + bevacizumab vs TAS-102 alone improved mOS 10.8 vs 7.5 mo (HR 0.61), PFS 5.6 vs 2.4 mo (HR 0.44), ORR 6.3% vs 1.0%. Combination is now the preferred 3L+ option per NCCN 2025. Distinct mechanism from prior fluoropyrimidine exposure (TS-independent, thymidine analog incorporation) — active in 5-FU-refractory disease. Hand-foot reactions notably less than fluoropyrimidine; main toxicity is myelosuppression.
Used By
Indication
IND-CRC-METASTATIC-3L-TAS102-BEV- IND-CRC-METASTATIC-3L-TAS102-BEV